EC
BEAM icon

Elmind Capital’s Beam Therapeutics BEAM Stock Holding History

Elmind Capital’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.3M Hold
476,338
– – 4.11% 12
2026
Q1 		$11.4M Hold
476,338
– – 3.22% 11
2025
Q4 		$13.2M Buy
+476,338
New +$12.2M 3.9% 9

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Elmind Capital's BEAM Position: Q2 2026 in Review

Elmind Capital held its Beam Therapeutics (BEAM) position steady in Q2 2026 at 476,338 shares worth $16.3M. The position accounts for 4.11% of the portfolio, ranked #12.

Elmind Capital first reported a position in BEAM in Q4 2025 and has held it in 3 quarters since. 277 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

  • Elmind Capital held 476,338 shares of Beam Therapeutics worth $16.3M as of Q2 2026.
  • Elmind Capital left its Beam Therapeutics share count unchanged in Q2 2026.
  • Beam Therapeutics made up 4.11% of Elmind Capital's portfolio in Q2 2026, its #12 holding.
  • Elmind Capital first reported a position in Beam Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 277 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Elmind Capital's 13F filing for Q2 2026, filed 14 Aug 2026.